These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19835825)

  • 21. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.
    Bernstein DI; Farley N; Bravo FJ; Earwood J; McNeal M; Fairman J; Cardin R
    Vaccine; 2010 May; 28(21):3748-53. PubMed ID: 19857450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
    Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
    J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.
    Freeman EE; White RG; Bakker R; Orroth KK; Weiss HA; Buvé A; Hayes RJ; Glynn JR
    Vaccine; 2009 Feb; 27(6):940-6. PubMed ID: 19071187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes.
    Dudek T; Mathews LC; Knipe DM
    Virology; 2008 Mar; 372(1):165-75. PubMed ID: 18006033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice.
    Liu W; Zhou Y; Wang Z; Zhang Z; Wang Q; Su W; Chen Y; Zhang Y; Gao F; Jiang C; Kong W
    Microbiol Immunol; 2017 May; 61(5):176-184. PubMed ID: 28378925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective immune correlates can segregate by vaccine type in a murine herpes model system.
    Sin JI; Ayyavoo V; Boyer J; Kim J; Ciccarelli RB; Weiner DB
    Int Immunol; 1999 Nov; 11(11):1763-73. PubMed ID: 10545480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estradiol improves genital herpes vaccine efficacy in mice.
    Pennock JW; Stegall R; Bell B; Vargas G; Motamedi M; Milligan G; Bourne N
    Vaccine; 2009 Sep; 27(42):5830-6. PubMed ID: 19660586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.
    Hu K; Dou J; Yu F; He X; Yuan X; Wang Y; Liu C; Gu N
    Vaccine; 2011 Feb; 29(7):1455-62. PubMed ID: 21185849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.
    Quenelle DC; Collins DJ; Rice TL; Prichard MN; Marciani DJ; Kern ER
    Antiviral Res; 2008 Nov; 80(2):223-4. PubMed ID: 18573279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.
    Chu CF; Meador MG; Young CG; Strasser JE; Bourne N; Milligan GN
    J Reprod Immunol; 2008 Jun; 78(1):58-67. PubMed ID: 17950908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective immunity to genital herpes simplex [correction of simpex] virus type 2 infection is mediated by T-bet.
    Svensson A; Nordström I; Sun JB; Eriksson K
    J Immunol; 2005 May; 174(10):6266-73. PubMed ID: 15879125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
    Bernstein DI; Cardin RD; Bravo FJ; Hamouda T; Pullum DA; Cohen G; Bitko V; Fattom A
    Vaccine; 2019 Oct; 37(43):6470-6477. PubMed ID: 31515143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.
    Bernstein DI; Cardin RD; Bravo FJ; Strasser JE; Farley N; Chalk C; Lay M; Fairman J
    Clin Vaccine Immunol; 2009 May; 16(5):699-705. PubMed ID: 19279167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.
    Durmanová V; Sapák M; Kosovský J; Rezuchová I; Kúdelová M; Buc M; Rajcáni J
    Folia Microbiol (Praha); 2008; 53(1):73-83. PubMed ID: 18481222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.